BMC sports science, medicine & rehabilitation · 2025
Twelve weeks of respiratory muscle training enhance respiratory function in CrossFit® athletes returning to exercise post-SARS-CoV-2 infection: single-blind randomized clinical trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fernández-Lázaro Diego, Seco-Calvo Jesús, Santamaría Gema, Donoso David Jerves, Roche Enrique, Garrosa Manuel
Аннотация
BACKGROUND: The Elevation Training Mask 2.0 (ETM) is a respiratory muscle device, designed to simulate altitude training. It works by reducing airflow through a valve system. During exercise, ETM could restore respiratory damage from post-infection phase of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), allowing ventilatory restriction that works as resistance training for respiratory muscles.
AIM: To comparatively evaluate the spirometry parameters in CrossFit® practitioners training using ETM (EG), compared to a control group (CG).
METHODS: In a single-blind randomized clinical trial, following the Consolidated Standards of Reporting Trials (CONSORT) recommendations, 20 trained male athletes were randomly assigned to an EG and a CG using simulated ETM device. Both groups completed 12 weeks of CrossFit® training after 1 month of finishing SARS-CoV-2 symptoms. Pre- (T1) and post-training (T2) testing included assessment of lung function and respiratory muscle strength.
RESULTS: No significant differences (p > 0.05) were observed comparing EG and CG in any of spirometry parameters evaluated. Nevertheless, significant differences (p < 0.05) in behavior were observed throughout the 36 training sessions for maximum voluntary ventilation (MVV) and maximum inspiratory pressure (MIP) with a strong effect (η²p = 0.693). In addition, significant improvements (p < 0.05) were observed in MIP and MVV exclusively in the EG when comparing T1 vs. T2.
CONCLUSION: The findings suggest that the inclusion of ETM in a 12-week CrossFit® training program, in athletes returning to exercise post-SARS-CoV-2 infection, may have modest benefits compared to CG on lung function and respiratory muscle strength.
PROTOCOL REGISTRATION: ClinicalTrials.gov, identifier (ID NCT06806124). 25/01/2025 retrospectively registered.
AIM: To comparatively evaluate the spirometry parameters in CrossFit® practitioners training using ETM (EG), compared to a control group (CG).
METHODS: In a single-blind randomized clinical trial, following the Consolidated Standards of Reporting Trials (CONSORT) recommendations, 20 trained male athletes were randomly assigned to an EG and a CG using simulated ETM device. Both groups completed 12 weeks of CrossFit® training after 1 month of finishing SARS-CoV-2 symptoms. Pre- (T1) and post-training (T2) testing included assessment of lung function and respiratory muscle strength.
RESULTS: No significant differences (p > 0.05) were observed comparing EG and CG in any of spirometry parameters evaluated. Nevertheless, significant differences (p < 0.05) in behavior were observed throughout the 36 training sessions for maximum voluntary ventilation (MVV) and maximum inspiratory pressure (MIP) with a strong effect (η²p = 0.693). In addition, significant improvements (p < 0.05) were observed in MIP and MVV exclusively in the EG when comparing T1 vs. T2.
CONCLUSION: The findings suggest that the inclusion of ETM in a 12-week CrossFit® training program, in athletes returning to exercise post-SARS-CoV-2 infection, may have modest benefits compared to CG on lung function and respiratory muscle strength.
PROTOCOL REGISTRATION: ClinicalTrials.gov, identifier (ID NCT06806124). 25/01/2025 retrospectively registered.